Muparfostat exhibits additional binding affinity toward lipoprotein lipase, thereby causing severe hyperlipidemia and ultimately exacerbating hepatic steatosis and liver damage, particularly in obese individuals.[21]. This evidence concerns the gene LPL and Hepatic steatosis.